Pittsburgh biotech firm involved in development of potential COVID-19 treatment

Michael Bayer, CFO of Wasabi Technologies, asked this rhetorical question in response to CFO’s inquiry about the business outlook for... read more

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from... read more

Pixability’s new study analyzes the YouTube practices of 215 beauty brands and 182,621 independent YouTube beauty creators who create YouTube... read more

Robotic lightweight wearable device empowers young adults with arm paralysis to live independently, while also reducing healthcare costs. read more

By 2050, there will be about 2 billion more mouths to feed, which means the global demand for food will... read more

RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the... read more

Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis... read more

A Phenix City man is among the estimated 200,000 or less people in the United States with an inherited condition... read more

CytoAgents, a Pittsburgh-based pharmaceutical company whose drug candidate battles a deadly side effect of respiratory illnesses like Covid-19, has reached... read more

There is a chronic global shortage of platelets to treat patients who are actively bleeding due to trauma or surgery,... read more